Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + Ibrutinib in Relapsed Mantle Cell Lymphoma
NCT02736617Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jul 2016
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by OHSU Knight Cancer Institute. Started Jul 2016; status: completed.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02736617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736617.